Risks of antipsychotics in old age, particularly in dementia: Review;Risiken von antipsychotika im alter, speziell bei Demenzen: Eine übersicht

Zeitschrift fur Gerontopsychologie und -psychiatrie

Volumn 22, Issue 1, 2009, Pages 17-56

  Wolter, Dirk K ^a,b  

^a Inn Salzach Klinikum   (Germany)

^b Inn Salzaeh Klinikum   (Germany)

Author keywords

Antipsychotics; Atypical neuroleptics; Dementia; Mortality; Old age; QT prolongation; Side effects; Sudden cardiac death

Indexed keywords

EID: 67649232878     PISSN: 10116877     EISSN: None     Source Type: Journal    
DOI: 10.1024/1011-6877.22.1.17     Document Type: Article

References (138)

1. Agency for Healthcare Research and Quality (AHRQ). (2007). Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. Verfügbar unter http://effectivehealthcare.ahrq.gov/repFiles/Atypical- Antipsychotics-Final-Repo rt.pdf Letzter Zugriff 20.01.2009.
2. Alanen, H. M., Finne-Soveri, H.. Fialova. D., Topinkova, E., Jonsson, P. V., Soerbye, L. W. et al. (2008). Use of antipsychotic medications in older home-care patients. Report from nine European countries. Aging Clinical and Experimental Research, 20, 260-265.
3. Alanen, H. M., Finne-Soveri, H. & Leinonen, E. (2008). Factors associated with non-use of antipsychotics among older residents with schizophrenia in long-term institutional care. International Journal of Geriatric Psychiatry, 23, 1261-1265.
4. APA. (2007). APA work group on Alzheimer's Disease and other dementias, Rabins, P. V., Blacker, D., Rovner, B. W, Rummans, T., Schneider, L. S., Tariot, P. N. et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. American Journal of Psychiatry, 164 (Suppl,), 5-56.
5. Ballard, C, Day, S., Sharp, S., Wing, G. & Sorensen, S. (2008). Neuropsychiatric symptoms in dementia: Importance and treatment considerations. International Review of Psychiatry, 20, 396-404.
6. Ballard, C, Hanney, M. L., Theodoulou, M., Douglas, S., Mc- Shane, R., Kossakowski, K. et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD) : Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151-157.
7. Ballard, C, Lana, M. M., Theodoulou, M., Douglas, S., McShane, R., Jacoby, R. et al. (2008). A randomised, blinded, placebocontrolled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). Public Library of Science Medicine, 5, e76.
8. Ballard, C, Waite, J. & Birks, J. (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Systematic Reviews, 25 (1), CD003476.
9. Bandelow, B., Grohmann, R. & Rüther, E. (2006). Unerwunschte Begleitwirkungen der Antipsychotika und ihre Behandlung. In H. J. Möller (Hrsg.), Therapie psychischer Erkrankungen (3. Aufl., S. 226-240). Stuttgart: Thieme.
10. Barak, Y., Baruch, Y., Mazeh, D., Paleacu, D. & Aizenberg, D. (2007). Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. American Journal of Geriatric Psychiatry, 15, 354-356.
11. Barnett, M. J., Perry, P. J., Alexander, B. & Kaboli, P. J. (2006). Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. Journal of Clinical Psychopharmacology, 26, 182-187.
12. Barnett, M. J., Wehring, H. & Perry, P. J. (2007). Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. Journal of Clinical Psychopharmacology, 27, 595-601.
13. Benkert, O. & Hippius, H. (2009). Kompendium der psychiatrischen Pharmakotherapie (7. Aufl.). Berlin: Springer.
14. BMJ Group. (2007). How safe are antipsychotics in dementia? Drug and Therapeutic Bulletin, 45, 81-85.
15. Bolton, J. M., Metge, C, Lix, L., Prior, H., Sareen, J. & Leslie, W. D. (2008). Fracture risk from psychotropic medications: A population-based analysis. Journal of Clinical Psychopharmacology, 28, 384-391.
16. Bont, L., Bosker, H. A., Brus, F, Yska, J. P. & Bosch, F. H. (1998). Torsade de pointes after pipamperone intoxication. Pharmacy World and Science, 20, 137.
17. Bronskill, S. E., Anderson, G. M., Sykora, K., Wodchis, W. P., Gill, S., Shulman, K. I. et al. (2004). Neuroleptic drug therapy in older adults newly admitted to nursing homes: Incidence, dose, and specialist contact. Journal of the American Geriatrics Society, 52, 749-755.
18. Brookhart, M. A., Rassen, J. A., Wang, P. S., Dormuth, C, Mogun, H. & Schneeweiss, S. (2007). Evaluating the validity of an instrumental variable study of neuroleptics: Can between-physician differences in prescribing patterns be used to estimate treatment effects? Medical Care, 45 (10 Suppl. 2), 116-122.
19. Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J. & Stürmer, T. (2006). Variable selection for propensity score models. American Journal of Epidemiology, 163, 1149-1156.
20. Brookhart, M. A., Wang, P. S., Solomon, D. H. & Schneeweiss, S. (2006). Evaluating short-term drug effects using a physicianspecific prescribing preference as an instrumental variable. Epidemiology, 17, 268-275.
21. Carson, S., McDonagh, M. S. & Peterson, K. (2006). A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. Journal of the American Geriatrics Society, 54, 354-361.
22. Cepeda, M. S., Boston, R., Farrar, J. T. & Strom, B. L. (2003). Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. American Journal of Epidemiology, 158, 280-287.
23. Committee on Safety of Medicines (CSM). (2004). Atypical antipsychotic drugs and stroke. Verfügbar unter http://www.mhra. gov. uk/home/groups/pl-p/documents/websiteresources/con019488.pdf Letzter Zugriff 20.01.2009.
24. Daiello, L. A. (2007). Atypical antipsychotics for the treatment of dementia-related behaviors: An update. Medicine and Health, Rhode Island, 90, 191-194.
25. Daumit, G. L., Goff, D. C., Meyer,. T. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P. et al. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research, 105, 175-187.
26. Deberdt, W. G., Dysken, M. W., Rappaport, S. A., Feldman, P. D., Young, C. A., Hay, D. P. et al. (2005). Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. American Journal of Geriatric Psychiatry, 13, 722-730.
27. De Clerck, F, Somers, Y, Mannaert, E., Greenspan, A. & Eerdekens, M. (2004). In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clinical Therapeutics, 26, 1261-1273.
28. Destatis. (2008). Statistisches Bundesamt: Sterbetafel Deutschland 2005/2007. Verfügbar unter http://www.destatis.de/jetspeed/portal/cms/ Sites/destatis/Internet/DE/Content/Statistik en/Bevoelkerung/ GeburtenSterbefaelle/Tabellen/Content l00 /SterbetafelDeutschland, templateId=renderPrint.psml Letzter Zugriff 30.1.2009.
29. Diener, H. C, Hacke, W. & Busch, E. (2003). Zerebrale Ischamie. In T. Brandt, J. Dichgans&H. C. Diener (Hrsg.), Therapie und Verlauf neurologischer Erkrankungen (4. Aufl., S. 345-358). Stuttgart: Kohlhammer.
30. Douglas, I. J. & Smeeth, L. (2008). Exposure to antipsychotics and risk of stroke: Self controlled case series study. British Medical, Journal, 337, 1227. doi: 10.1136/bmj.al227.
31. Drici. M. D. & Clément. N. (2001). Is gender a risk factor for adverse drug reactions'? The example of drug-induced long QT syndrome. Drug Safety, 24, 575-585.
32. Drici, M. D. & Priori, S. (2007). Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety, 16, 882-890.
33. European Medicines Agency (EMEA). (2008a). Begründung. Verfügbar unter http://www.emea.europa.eu/pdfs/human /opiniongen/ Conventional-%20Antipsyehotics-Artiele5.3-Appendixl-CHMPAR.pdf Letzter Zugriff 25.1.2009.
34. European Medicines Agency (EMEA). (2008b). Warnung. Verfügbar unter http://www.emea.europa.eu/pdfs/human/opiniongen/Conventional- Antipsychotics-Article5.3-CHMP-Opinion.pdf Letzter Zugriff 25.1.2009.
35. Fassbender, K., Deuschl, G., Dodel, R., Förstl, H., Frolich, L., Heneka, M. et al. (2008). Therapie neurodegenrativer Demenzen. In Kommission «Leitlinien der Deutschen Gesellschaft fur Neurologie», H. C. Diener, N. Putzki, P. Berlit, G. Deutschl, C. Elger, R. Gold et al. (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie (4. Aufl., S. 167-176). Stuttgart: Thieme.
36. Food and Drug Administration (FDA). (2005). Warnung. Verfügbar unter http://www.fda.gov/cder/drug/advisory/antipsychotics.htm Letzter Zugriff 25.1.2009.
37. Food and Drug Administration (FDA). (2008). Warnung. Verfügbar unter http://www.fda.gov/CDER/drug/InfoSheets/HCP /antipsychotics-conventional.htm Letzter Zugriff 25.1.2009.
38. Finkel, S., Kozma, C, Long, S., Greenspan, A., Mahmoud, R., Baser, O. et al. (2005). Risperidone treatment in elderly patients with dementia: Relative risk of cerebrovascular events versus other antipsychotics. International Psychogeriatrics, 17, 617-629.
39. Fric, M., Laux, G., Rao, M. L., Schmidmaier, R., Eberl, J., Kirchmeier, T. et al. (2004). Plasmaspiegel von Risperidon bei Alterspatienten mit Demenz. Psychopharmakotherapie, 11, 90-94.
40. GBE. (2009). Gesundheitsberichterstattung des Bundes. Verfügbar unter http://www.gbe-bund.de/oowa921-install/servlet /oowa/aw92/dboowasys921.xwdevkit/xwd-init?gbe.isgbetol/xs-start-neu/386139393/ 89493397 Letzter Zugriff 30.1. 2009.
41. Gibbs, R. G. J., Newson, R., Lawrenson, R., Greenhalgh, R. M. & Davies, A. H. (2001). Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996 experience of a national primary care database. Stroke, 32, 1085-1090.
42. Gill, S. S., Bronskill, S. E., Normand, S. L., Anderson, G. M., Sykora, K., Lam, K. et al. (2007). Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine, 146, 775-786.
43. Gill, S. S., Rochon, P. A., Herrmann, N., Lee, P. E., Sykora, K., Gunraj, N. et al. (2005). Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. British Medical Journal, 330, 445.
44. Grander, G. (2008). Antipsychotika. In F. Holsboer, G. Gründer&O. Benkert (Hrsg.), Handbuch der Psychopharmakotherapie (S. 591-626). Berlin: Springer.
45. Gruneir, A., Lapane, K. L., Miller, S. C. & Mor, V (2008a). Does the presence of a dementia special care unit improve nursing home quality? Journal of Aging and Health, 20, 837-854.
46. Gruneir, A., Lapane, K. L., Miller, S. C. & Mor, V. (2008b). Is dementia special care really special? A new look at an old question. Journal of the American Geriatrics Society, 56, 199-205.
47. Gupta, A., Lawrence, A. T, Krishnan, K., Kavinsky, C. J. & Trohman, R. G. (2007). Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. American Heart Journal, 153, 891-899.
48. Hägg, S., Bate, A., Stahl, M. & Spigset, O. (2008). Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Safety, 31, 685-694.
49. Hagg, S. & Spigset, O. (2002). Antipsychotic-induced venous thromboembolism: A review of the evidence. CNS Drugs, 16, 765-776.
50. Hagen, B, Esther, C. A., Ikuta, R, Williams, R. J., Le Navenec, C. L. & Aho, M. (2005). Antipsychotic drug use in Canadian long-term care facilities: Prevalence, and patterns following resident relocation. International Psychogeriatrics, 17, 179-193.
51. Hamanaka, S., Kamijo, Y., Nagai, T, Kurihara, K., Tanaka, K., Soma, K. et al. (2004). Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circulation Journal, 68, 850-852.
52. Hartikainen, S., Rahkonen, T, Kautiainen, H. & Sulkava, R. (2005). The use of psychotropics and survival in demented elderly individuals. International Clinical Psychopharmacology, 20, 227-231.
53. Haupt, M., Cruz-Jentoft, A. & Jeste, D. (2006). Mortality in elderly dementia patients treated with risperidone. Journal of Clinical Psychopharmacology, 26, 566-570.
54. Haverkamp, W. & Deuschle, M. (2006). An tipsy chotikainduzierte QT-Verlängerung. Nervenarzt, 77, 276-288.
55. Haw, C, Stubbs, J. & Yorston, G. (2008). Antipsychotics for BPSD: An audit of prescribing practice in a specialist psychiatric inpatient unit. International Psychogeriatrics, 20, 790-799.
56. Health Canada. (2005). Warnung. Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Verfügbar unter http://www.hcsc.gc.ea/ahc-asc/media/advisories-avis/-2005/ 2005-63-eng. php Letzter Zugriff 25.1.2009.
57. Herrmann, N. & Lanctôt, K. L. (2006). Atypical antipsychotics for neuropsychiatric symptoms of dementia: Malignant or maligned? Drug Safety, 29, 833-843.
58. Herrmann, N., Mamdani, M. & Lanctôt, K. L. (2004). Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry, 161, 1113-1115.
59. Hiemke, C. & Baumann, P. (2008). Spezielle Arzneimittelinteraktionen. In F. Holsboer, G. Gründer&O. Benkert (Hrsg.), Handbuch der Psychopharmakotherapie (S. 1127-1144). Berlin: Springer.
60. Hienle, T. T., Cumming, R. G., Cameron, I. D., Chen, J. S., Lord, S. R., March, L. M. et al. (2005). Atypical antipsychotic medications and risk of falls in residents of aged care facilities. Journal of the American Geriatrics Society, 53, 1290-1295.
61. Hollis, J., Forrester, L., Brodaty, H., Touyz, S., Cumming, R. & Grayson, D. (2007a). Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Australian and New Zealand Journal of Psychiatry, 41, 751-758.
62. Hollis, J., Grayson, D., Forrester, L., Brodaty, H., Touyz, S. & Cumming, R. (2007b). Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. American Journal of Geriatric Psychiatry, 15, 932-941.
63. Hollis, J., Touyz, S., Grayson, D. & Forrester, L. (2006). Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001. Australian and New Zealand Journal of Psychiatry, 40, 981-986.
64. Hosia-Randell, H. & Pitkälä, K. (2005). Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs and Aging, 22, 793-800.
65. Hugenholtz, G. W., Heerdink, E. R., van Staa, T. P., Nolen, W. A. & Egberts, A. C. (2005). Risk of hip/femur fractures in patients using antipsychotics. Bone, 37, 864-870.
66. Hui, W. K., Mitchell, L. B., Kavanagh, K. M., Gillis, A. M., Wyse, D. G., Manyari, D. E. et al. (1990). Melperone: Electrophysiologic and antiarrhythmic activity in humans. Journal of Cardiovascular Pharmacology, 15, 144-149.
67. Jeste, D. V., Blazer, D., Casey, D., Meeks, T., Salzman, C, Schneider, L. et al. (2008). ACNP white paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology, 33, 957-970.
68. Jönsson, A. K., Brudin, L., Ahlner, J., Hedenmalm, K., Eriksson, A. & Hägg, S. (2008). Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. International Clinical Psychopharmacology, 23, 263-268.
69. Kales, H. C, Valenstein, M., Kim, H. M., McCarthy, J. E, Ganoczy, D., Cunningham, F. et al. (2007). Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. American Journal of Psychiatry, 164, 1568-1576.
70. Kamble, P., Chen, H., Sherer, J. & Aparasu, R. R. (2008). Antipsychotic drug use among elderly nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy, 6, 187-197.
71. Kannankeril, P. J. & Roden, D. M. (2007). Drug-induced long QT and torsade de pointes: Recent advances. Current Opinion in Cardiology, 22, 39-43.
72. Kim, H. & Whall, A. L. (2006). Factors associated with psychotropic drug usage among nursing home residents with dementia. Clinical Nursing Research, 55, 252-258.
73. Kleijer, B. C., van Marum, R. J., Egberts, A. C, Jansen, P. A., Knol, W. & Heerdink, E. R. (2008). Risk of cerebrovascular events in elderly users of antipsychotics. Journal of Psychopharmacology. 2008. Jul. 17. [Epub ahead of print] doi: 10.1177/0269881108093583.
74. Knol, W., van Marum, R. J., Jansen, P. A., Souverein, P. C., Schobben, A. F. & Egberts, A. C. (2008). Antipsychotic drug use and risk of pneumonia in elderly people. Journal of the American Geriatrics Society, 56, 661-666.
75. Kryzhanovskaya, L. A., Jeste, D. V., Young, C. A., Polzer, J. P., Roddy, T. E., Jansen, J. F. et al. (2006). A review of treatmentemergent adverse events during olanzapine clinical trials in elderly patients with dementia. Journal of Clinical Psychiatry, 67, 933-945.
76. Lacut, K., Le Gal, G., Couturaud, E, Cornily, G., Leroyer, C, Mottier, D. et al. (2007). Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: Results from the EDITH case-control study. Fundamental and Clinical Pharmacology, 21, 643-650.
77. Lange-Asschenfeldt, C. (2008). Psychopharmakabei internistischen Erkrankungen. In F. Holsboer, G. Gründer&O. Benkert (Hrsg.), Handbuch der Psychopharmakotherapie (S. 1072-1080). Berlin: Springer.
78. Lanctot, K. L., Best, T. S., Mittmann, N., Liu, B. A., Oh, P. I., Einarson, T. R. et al. (1998). Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. Journal of Clinical Psychiatry, 59, 550-561.
79. Lautenschlager, M. M., Lautenschlager, N. T. & Förstl, H. (2008). Psychopharmaka im Alter. In F. Holsboer, G. Gründer&O. Benkert (Hrsg.), Handbuch der Psychopharmakotherapie (S. 1081-1092). Berlin: Springer.
80. Layton, D., Harris, S., Wilton, L. V. & Shakir, S. A. (2005). Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. Journal of Psychopharmacology, 19, 473-482.
81. Lee, P. E., Fischer, H. D., Rochon, P. A., Gill, S. S., Herrmann, N., Bell, CM. et al. (2008). Published randomized controlled trials of drug therapy for dementia often lack complete data on harm. Journal of Clinical Epidemiology, 61, 1152-1160.
82. Lee, P. E., Gill, S. S., Freedman, M., Bronskill, S. E., Hillmer, M. P. & Rochon, P. A. (2004). Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: Systematic review. British Medical Journal, 329 (7457), 75. Epub 2004 Jun. 11.
83. Lin, C. H., Chen, M. C., Wang, S. Y. & Lin, C. Y. (2004). Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. Journal of the Formosan Medical Association, 103, 437-441.
84. Liperoti, R., Gambassi, G., Lapane, K. L., Chiang, C, Pedone, C, Mor, V. & Bernabei, R. (2005a). Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Journal of Clinical Psychiatry, 66, 1090-1096.
85. Liperoti, R., Gambassi, G., Lapane, K. L., Chiang, C, Pedone, C, Mor, V. & Bernabei, R. (2005b). Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine, 165, 696-701.
86. Liperoti, R., Onder, G., Lapane, K. L., Mor, V., Friedman, J. H., Bernabei, R. et al. (2007). Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: Results of a case-control study. Journal of Clinical Psychiatry, 68, 929-934.
87. Liperoti, R., Pedone, C, Lapane, K. L., Mor, V., Bernabei, R. & Gambassi, G. (2005). Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Archives of Internal Medicine, 165, 2677-2682.
88. Locca, J. E, Biila, C. J., Zumbach, S. & Bugnon, O. (2008). Pharmacological treatment of behavioral and psychological symptoms of dementia (BPSD) in nursing homes: Development of practice recommendations in a Swiss canton. Journal of the American Medical Directors Association, 9, 439-448.
89. Lohse, M. J. & Müller-Oerlinghausen, B. (2008). Psychopharmaka. In U. Schwabe&D. Paffrath (Hrsg.), Arzneiverordnungsreport 2008 (S. 773-817) Berlin: Springer.
90. Lovheim, H., Sandman, P. O., Kallin, K., Karlsson, S. & Gustafson, Y. (2006). Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. International Psycho geriatrics, 18, 713-726. Epub 2006 Jul. 31.
91. Mazzucco, S., Cipriani, A., Barbui, C. & Monaco, S. (2008). Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: A systematic review. Mini Reviews in Medicinal Chemistry, 8, 776-783.
92. Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M. et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophrenia Research, 101, 273-286.
93. Medicines and Healthcare Products Regulatory Agency (MHRA). (2004). Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia. Verfügbar unter http://www.mhra.gov. uk/Safetyinformation/ Safetywamingsale rtsandrecalls/Safetywarnin gsandmessagesformedicines /CON1004298 oder http://www.mhra.gov. uk/home/groups/plp/documents/ websiteresources/con019490.pdf Letzter Zugriff 20.01.2009.
94. Monette, J., Champoux, N., Monette, M., Fournier, L., Wolfson, C, du Fort, G. G. et al. (2008). Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. International Journal of Geriatric Psychiatry, 23, 574-579.
95. New York Times. (2009, 15. Januar). Lilly said to be near $1.4 billion U. S. Settlement. Verfiigbar unter http://www.nytimes.com/2009/0 l/15/business/15drug.html?-r=2 Letzter Zugriff 20.01.2009.
96. National Institute for Health and Clinical Excellence (NICE). (2006). Dementia. Supporting people with dementia and their carers in health and social care. Verfügbar unter http://www.nice.org.uk/nicemedia/pdf/ CG042NICEGuideline.pdf Letzter Zugriff 20.01.2009.
97. Nobili, A., Piana, I., Balossi, L., Pasina, L., Matucci, M., Tarantola, M. et al. (2008). Alzheimer special care units compared with traditional nursing home for dementia care: Are there differences at admission and in clinical outcomes? Alzheimer disease and Associated Disorders, 22, 352-361.
98. Oborne, C. A., Hooper, R., Li, K. C, Swift, C. G. & Jackson, S. H. (2002). An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing, 31, 435-439.
99. Percudani, M., Barbui, C, Fortino, I., Tansella, M. & Petrovich, L. (2005). Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Journal of Clinical Psychopharmacology, 25, 468-470.
100. Pouwels, S., van Staa, T. P., Egberts, A. C, Leufkens, H. G., Cooper, C. & de Vries, F. (2009). Antipsychotic use and the risk of hip/femur fracture: A population-based case-control study. Osteoporosis International. 2009 Jan 21. [Epub ahead of print] doi 10.1007/s00 198-008-0826-5.
101. Rädler, T, Jahn, H. & Wiedemann, K. (2007). Psychopharmakologie. In A. Rohde&A. Mameros (Hrsg.), Geschlechtsspezifische Psychiatrie und Psychotherapie (S. 377-383). Stuttgart: Kohlhammer.
102. Raivio, M. M., Laurila, J. V., Strandberg, T. E., Tilvis, R. S. & Pitkälä, K. H. (2007). Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: A two-year prospective study. American Journal of Geriatric Psychiatry, 15, 416-424.
103. Rapoport, M., Mamdani, M., Shulman, K. I., Herrmann, N. & Rochon, P. A. (2005). Antipsychotic use in the elderly: Shifting trends and increasing costs. International Journal of Geriatric Psychiatry, 20, 749-753.
104. Ray, W. A., Chung, C. P., Murray, K. T., Hall, K. & Stein, CM. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. The New England Journal of Medicine, 360, 225-235.
105. Ray, W. A., Meredith, S., Thapa, P. B., Meador, K. G., Hall, K. & Murray, K. T. (2001). Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58, 1161-1167.
106. Royal College of Psychiatrists, Faculty for the Psychiatry of Old Age (RCPsych). (2004). Atypical antipsychotics and behavioural and psychiatric symptoms of dementia. Prescribing update for old age psychiatrists. Verfügbar unter http://www.rcpsych.ac.uk/pdf/Atypicalguidance.pdf Zugriff 20.01.2009 Identischer Text mit neuem Layout 20.09.2005: http://www.rcpsych.ac. uk/pdf/BPSD.pdf Letzter Zugriff 20.01.2009.
107. Rochon, P. A., Normand, S. L., Gomes, T, Gill, S. S., Anderson, G. M., Melo, M. et al. (2008). Antipsychotic therapy and shortterm serious events in older adults with dementia. Archives of Internal Medicine, 168, 1090-1096.
108. Rosenheck, R. A., Leslie, D. L., Sindelar, J. L., Miller, E. A., Tariot, P. N., Dagerman, K. S. et al. (2007). Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Archives of General Psychiatry, 64, 1259-1268.
109. Rott, C. (2004). Demographic des hohen und sehr hohen Alters. In A. Kruse&M. Martin (Hrsg.), Enzyklopädie der Geriatrie (S. 51-65). Bern: Huber.
110. Ruths, S., Straand, J., Nygaard, H. A. & Aarsland, D. (2008). Stopping antipsychotic drug therapy in demented nursing home patients: A randomized, placebo-controlled study - The Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 23, 889-895.
111. Sacchetti, E., Trifirò, G., Caputi, A., Turrina, C, Spina, E., Cricelli, C. et al. (2008). Risk of stroke with typical and atypical anti-psychotics: A retrospective cohort study including unexposed subjects. Journal of Psychopharmacology, 22, 39-46.
112. Schäufele, M., Lode, S., Hendlmeier, I., Köhler, L. & Weyerer, S. (2008). Demenzkranke in der stationären Altenhilfe. Aktuelle Inanspruchnahme, Versorgungskonzepte und Trends am Beispiel Baden-Württembergs. Stuttgart: Kohlhammer.
113. Schneeweiss, S. & Avorn, J. (2009). Antipsychotic agents and sudden cardiac death - How should we manage the risk? The New England Journal of Medicine, 360, 294-296.
114. Schneeweiss, S. & Maclure, M. (2000). Use of comorbidity scores for control of confounding in studies using administrative databases. International Journal of Epidemiology, 29, 891-898.
115. Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C. & Wang, P. S. (2007). Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal, 176, 627-632.
116. Schneider, L. S., Dagerman, K. S. & Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 294, 1934-1943.
117. Schneider, L. S., Dagerman, K. & Insel, P. S. (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: Metaanalysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191-210.
118. Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S. et al. (CATIE-AD Study Group). (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine, 355, 1525-1538.
119. Schwabe, U. (2008). Arzneiverordnungen für ältere Patienten. In U. Schwabe&D. Paffrath (Hrsg.), Arzneiverordnungsreport 2008 (S. 923-960). Berlin: Springer.
120. Setoguchi, S., Wang, P. S., Brookhart, M., Canning, C. F., Kaci, L. & Schneeweiss, S. (2008). Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. Journal of the American Geriatrics Society, 56, 1644-1650.
121. Sicouri, S. & Antzelevitch, C. (2008). Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opinion on Drug Safety, 7, 181-194.
122. Scottish Intercollegiate Guidelines Network (SIGN). (2006). Management of patients with dementia. A national clinical guideline. Guideline Nr. 86. Verfügbar unter http://www.sign. ac. uk/pdf/sign86.pdf Letzter Zugriff 20.1.2009.
123. Sink, K. M., Holden, K. F. & Yaffe, K. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. Journal of the American Medical Association, 293, 596-608.
124. Snowdon, J., Day, S. & Baker, W. (2005). Why and how antipsychotic drugs are used in 40 Sydney nursing homes. International Journal of Geriatric Psychiatry, 20, 1146-1152.
125. Stöllberger, C., Huber, J. O. & Finsterer, J. (2005). Antipsychotic drugs and QT prolongation. International Clinical Psychopharmacology, 20, 243-251.
126. Straus, S. M., Bleumink, G. S., Dieleman, J. P., van derLei, J., 't Jong, G. W., Kingma, J. H. et al. (2004). Antipsychotics and the risk of sudden cardiac death. Archives of Internal Medicine, 164, 1293-1297.
127. Suh, G. H. & Shah, A. (2005). Effect of antipsychotics on mortality in elderly patients with dementia: A 1-year prospective study in a nursing home. International Psychogeriatrics, 17, 429-441.
128. Takkouche, B., Montes-Martínez, A., Gill, S. S. & Etminan, M. (2007). Psychotropic medications and the risk of fracture: A meta-analysis. Drug Safety, 30, 171-184.
129. Trifirò, G., Spina, E. & Gambassi, G. (2009). Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile? Pharmacology Research, 59, 1-12.
130. Trifirò, G., Verhamme, K. M., Ziere, G., Caputi, A. P., Strieker, B. H. & Sturkenboom, M. C. (2007). All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiology and Drug Safety, 16, 538-544.
131. Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H. et al. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. The New England Journal of Medicine, 353, 2335-2341.
132. Wang, P. S., Schneeweiss, S., Setoguchi, S., Patrick, A., Avom, J., Mogun, H. et al. (2007). Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. Journal of Clinical Psychopharmacology, 27, 707-710.
133. Weyerer, S. & Bickel, H. (2007). Epidemiologie psychischer Erkrankungen im höheren Lehensalter. Stuttgart: Kohlhammer.
134. Weyerer, S., Schäufele, M., Hendlmeier, I., Kofahl, C. & Sattel, H. (2006). Demenzkranke in Pflegeeinrichtungen. Besondere und traditionelle Versorgung im Vergleich. Stuttgart: Kohlhammer.
135. Witchel, H. J., Hancox, J. C. & Nutt, D. J. (2003). Psychotropic drugs, cardiac arrhythmia, and sudden death. Journal of Clinical Psychopharmacology, 23, 58-77.
136. Wood-Mitchell, A., James, I. A., Waterworth, A., Swann, A. & Ballard, C. (2008). Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: A qualitative study. Age Ageing, 37, 547-552.
137. Wooltorton, E. (2002). Risperidone (Risperdal) : Increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 167, 1269-1270.
138. Zornberg, G. L. & Jick, H. (2000). Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: A casecontrol study. The Lancet, 356, 1219-1223.